<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03239496</url>
  </required_header>
  <id_info>
    <org_study_id>IPV004</org_study_id>
    <nct_id>NCT03239496</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Immunogenicity of Intramuscular Full-Dose and Intradermal Fractional Dose of IPV</brief_title>
  <official_title>A Phase 3, Open-label, Multicenter Randomized Trial to Evaluate Humoral Immunogenicity of Various Schedules of Intramuscular Full-Dose and Intradermal Fractional Dose of Inactivated Polio Vaccine in Latin American Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fidec Corporation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bill and Melinda Gates Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fidec Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will assess and compare the immune response to full-dose inactivated polio vaccines
      (IPV) via intramuscular (IM) administration and of the fractional dose of inactivated
      poliovirus vaccine (f-IPV) via intradermal (ID) administration, in different schedule
      combinations in the Expanded Program on Immunization (EPI) primary series.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study prioritizes comparisons involving two-dose regimens recently recommended by the
      World Health Organization (WHO) Strategic Advisory Group of Experts on immunization (SAGE)
      and Pan American Health Organization (PAHO) in response to global IPV supply shortages 21.
      Furthermore, the study will provide data on the comparative humoral immunogenicity of various
      schedules to inform polio immunization policy for the post-eradication era.

      The study population will include infants in Dominican Republic and Panama. Absence of wild
      and circulating vaccine derived polioviruses along with the lack of regular Supplementary
      Immunization Activities (SIAs) in the Latin America region provide an ideal epidemiologic
      setting to study polio vaccine immunogenicity.

      Infants will receive two or three doses of full-dose IPV IM or f-IPV ID, in two schedules
      (10, 14 and 36 weeks and 14 and 36 weeks). Immunological and safety assessments will be made
      after one dose, two doses and three doses.

      A total of 773 infants will be enrolled and distributed into 4 groups, according to a
      randomization scheme. During the study period, infants will be administered other concomitant
      vaccines according to the national schedules of the participating countries, but the effect,
      if any, of the concomitant administration on IPV immunogenicity will not be assessed.

      Optimum immunogenicity expected from the dose(s) of IPV in the post-eradication era will have
      to be balanced with the cost and supply constraints of IPV. This study will be critical to
      determine how many doses of IPV and which schedule are optimal for the post-eradication era
      after the global cessation of Oral Polio Vaccine (OPV) use.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 23, 2017</start_date>
  <completion_date type="Anticipated">March 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 5, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Seroconversion non-inferiority of 2 doses f-IPV ID vs 2 doses IPV IM</measure>
    <time_frame>To be assessed 4 weeks after the last dose</time_frame>
    <description>To determine if the seroconversion rate of a 2-dose intradermally administered fractional-dose inactivated poliovirus vaccine (f-IPV) regimen administered at 14 and 36 weeks of age is non-inferior to that of a 2-dose intramuscularly administered inactivated poliovirus vaccine (IPV) regimen administered at 14 and 36 weeks of age for poliovirus serotypes 1 and 2.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Seroconversion non-inferiority of 2 doses IPV IM vs 3 doses IPV IM</measure>
    <time_frame>To be assessed 4 weeks after the last dose</time_frame>
    <description>To determine if the seroconversion rate of a 2-dose IPV regimen administered at 14 and 36 weeks of age is non-inferior to that of a 3-dose IPV regimen administered at 10, 14, and 36 weeks of age for poliovirus serotypes 1 and 2.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Seroconversion non-inferiority of 2 doses f-IPV ID vs 3 doses f-IPV ID</measure>
    <time_frame>To be assessed 4 weeks after the last dose</time_frame>
    <description>To determine if the seroconversion rate of a 2-dose f-IPV regimen administered at 14 and 36 weeks of age is non-inferior to that of a 3-dose f-IPV regimen administered at 10, 14, and 36 weeks of age for poliovirus serotypes 1 and 2.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Seroconversion superiority of 2 doses IPV IM at different schedules</measure>
    <time_frame>To be assessed 4 weeks after the second dose</time_frame>
    <description>To determine if the seroconversion rate of a 2-dose IPV regimen administered at 14 and 36 weeks of age is superior to that of a 2-dose IPV regimen administered at 10 and 14 weeks of age for poliovirus serotypes 1 and 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroconversion superiority of 2 dose f-IPV ID at different schedules</measure>
    <time_frame>To be assessed 4 weeks after the second dose</time_frame>
    <description>To determine if the seroconversion rate of a 2-dose f-IPV regimen administered at 14 and 36 weeks of age is superior to that of a 2-dose f-IPV regimen administered at 10 and 14 weeks of age for poliovirus serotypes 1 and 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroconversion non-inferiority of 2 dose f-IPV ID vs 3 dose IPV IM</measure>
    <time_frame>To be assessed 4 weeks after the last dose</time_frame>
    <description>To determine if the seroconversion rate of a 2-dose f-IPV regimen administered at 14 and 36 weeks of age is non-inferior to that of a 3-dose IPV regimen administered at 10, 14, and 36 weeks of age for poliovirus serotypes 1 and 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroconversion non inferiority of 3 doses f-IPV ID vs 3 doses IPV IM</measure>
    <time_frame>To be assessed 4 weeks after the last dose</time_frame>
    <description>To determine if the seroconversion rate of a 3-dose f-IPV regimen administered at 10, 14, and 36 weeks of age is non-inferior to that of a 3-dose IPV regimen also administered at 10, 14, and 36 weeks of age for poliovirus serotypes 1 and 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroconversion non inferiority of 3 doses f-IPV ID vs 2 doses IPV IM</measure>
    <time_frame>To be assessed 4 weeks after the last dose</time_frame>
    <description>To determine if the seroconversion rate to a 3-dose regimen of f-IPV administered at 10, 14, and 36 weeks of age is non-inferior to that of a 2-dose IPV regimen administered at 14 and 36 weeks of age for poliovirus serotypes 1 and 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of SAEs, IMEs and severe local reactions</measure>
    <time_frame>To be assessed throughout the complete study period, approx. 13 months</time_frame>
    <description>To assess the safety of each vaccine (IPV and f-IPV) as measured by the incidence of serious adverse events (SAEs), important medical events (IMEs) and severe local reactions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NAbs</measure>
    <time_frame>To be assessed 4 weeks after the last dose of each immunization schedule</time_frame>
    <description>To assess all primary and secondary immunogenicity objectives through comparison of neutralizing antibody (NAb) titers.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">773</enrollment>
  <condition>Poliomyelitis</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 doses IPV IM at 10, 14 &amp; 36 weeks of age incl. blood sampling at 10, 14, 18 &amp; 40 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 doses IPV IM at 14 &amp; 36 weeks of age incl. blood sampling at 14, 18, 36 &amp; 40 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 doses f-IPV ID at 10, 14 &amp; 36 weeks of age incl. blood sampling at 10, 14, 18 &amp; 40 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 doses f-IPV ID at 14 &amp; 36 weeks of age incl. blood sampling at 14, 18, 36 &amp; 40 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IPV</intervention_name>
    <description>Comparison of different vaccination schedules with 2 different vaccines (IPV and f-IPV) and 2 different types of administration (IM and ID)</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>f-IPV</intervention_name>
    <description>Comparison of different vaccination schedules with 2 different vaccines (IPV and f-IPV) and 2 different types of administration (IM and ID)</description>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_label>Group D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Infants of 6 weeks of age (-7 to + 7 days) on date of enrollment.

          2. Healthy, as assessed from medical history and physical examination by a study
             physician,

          3. Written informed consent obtained from parents or legal representatives who have been
             properly informed about the study and are able to comply with planned study
             procedures.

        Exclusion Criteria:

          1. Vaccinated with any poliovirus vaccine prior to inclusion,

          2. A household contact with OPV vaccination history in the past 4 weeks,

          3. HIV infection or pharmacologic immunosuppression,

          4. Known allergy to any component of the study vaccines (phenoxyethanol, formaldehyde),

          5. Uncontrolled coagulopathy or blood disorder contraindicating intramuscular and
             intradermal injections,

          6. Acute severe febrile illness on day of vaccination deemed by the Investigator(s) to be
             a contraindication for vaccination,

          7. Not suitable for inclusion or is unlikely to comply with the protocol in the opinion
             of the investigator(s).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Weeks</minimum_age>
    <maximum_age>7 Weeks</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital Universitario Nuestra Se√±ora de la Alta Gracia</name>
      <address>
        <city>Santo Domingo</city>
        <country>Dominican Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cevaxin Vaccination Center</name>
      <address>
        <city>David</city>
        <country>Panama</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cevaxin Vaccination Center</name>
      <address>
        <city>La Chorrera</city>
        <country>Panama</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cevaxin Vaccination Center</name>
      <address>
        <city>Panama city</city>
        <country>Panama</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Dominican Republic</country>
    <country>Panama</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 28, 2017</study_first_submitted>
  <study_first_submitted_qc>August 1, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 4, 2017</study_first_posted>
  <last_update_submitted>March 27, 2018</last_update_submitted>
  <last_update_submitted_qc>March 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Poliomyelitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

